Clinical Trial Update: Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating nivolumab alone or with ipilimumab vs standard follow-up as immunotherapy for surgically resectable head and neck cancer aft…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Universitätsklinikum Hamburg-Eppendorf | Conditions: Head and Neck Cancer | Phase 3 | Status: UNKNOWN